Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajkumar, S. V.
Right arrow Articles by Greipp, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajkumar, S. V.
Right arrow Articles by Greipp, P. R.
Clinical Cancer Research Vol. 6, 3111-3116, August 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma1

S. Vincent Rajkumar2, Traci Leong, Patrick C. Roche, Rafael Fonseca, Angela Dispenzieri, Martha Q. Lacy, John A. Lust, Thomas E. Witzig, Robert A. Kyle, Morie A. Gertz and Philip R. Greipp

Divisions of Hematology [S. V. R., R. F., A. D., M. Q. L., J. A. L., T. E. W., R. A. K., M. A. G., P. R. G.] and Anatomic Pathology [P. C. R.], Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, and the Eastern Cooperative Oncology Group, Brookline, Massachusetts 02445 [T. L.]

We studied the prognostic value of angiogenesis grading and microvessel density estimation in newly diagnosed multiple myeloma. Seventy-five patients with newly diagnosed myeloma, treated on Eastern Cooperative Oncology Protocol E9486 and Intergroup study 0141 (S9321) at the Mayo Clinic, were studied. Bone marrow microvessels were examined using immunohistochemical staining for von Willebrand factor. Determination of microvessel density and angiogenesis grading was done in a blinded manner. There was a strong correlation between microvessel density and the plasma cell labeling index, rho 0.42, P < 0.001. Angiogenesis grade was also significantly associated with the plasma cell labeling index. Fifteen % of patients with low-grade angiogenesis had a high labeling index (>1%). In contrast, 47% of patients with intermediate or high-grade angiogenesis had high labeling indices (P = 0.02). Overall survival was significantly different among those with high-, intermediate-, and low-grade angiogenesis, with median times of 2, 4, and 4.4 years, respectively (P = 0.02). Similarly, patients with microvessel density >50/x400 field had poorer survival compared with those with 50 or fewer microvessels/field, median survival 2.6 versus 5.1 years, respectively (P = 0.004). There was a strong association between angiogenesis grade and microvessel density (P < 0.001). We conclude that bone marrow angiogenesis is a predictor of poor survival in newly diagnosed myeloma. Angiogenesis is correlated with the plasma cell labeling index but not the bone marrow plasma cell percentage. A simple visual grading of angiogenesis is an efficient alternative to microvessel density estimation.




This article has been cited by other articles:


Home page
 BloodHome page
D. Hose, J. Moreaux, T. Meissner, A. Seckinger, H. Goldschmidt, A. Benner, K. Mahtouk, J. Hillengass, T. Reme, J. De Vos, et al.
Induction of angiogenesis by normal and malignant plasma cells
Blood, July 2, 2009; 114(1): 128 - 143.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. T.-F. Shih, H.-A. Hou, C.-Y. Liu, B.-B. Chen, J.-L. Tang, H.-Y. Chen, S.-Y. Wei, M. Yao, S.-Y. Huang, W.-C. Chou, et al.
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival
Blood, April 2, 2009; 113(14): 3161 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. Lin, A. Luciani, K. Belhadj, P. Maison, A. Vignaud, J.-F. Deux, P. Zerbib, F. Pigneur, E. Itti, H. Kobeiter, et al.
Patients with Plasma Cell Disorders Examined at Whole-Body Dynamic Contrast-enhanced MR Imaging: Initial Experience
Radiology, March 1, 2009; 250(3): 905 - 915.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al.
Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Blood, August 15, 2008; 112(4): 1346 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
K. Anargyrou, E. Terpos, T. P. Vassilakopoulos, A. Pouli, S. Sachanas, T. Tzenou, S. Masouridis, D. Christoulas, M. K. Angelopoulou, E. M. Dimitriadou, et al.
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
Haematologica, March 1, 2008; 93(3): 451 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. J.A. Auwerda, P. Sonneveld, M. P.M. de Maat, and F. W.G. Leebeek
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma
Haematologica, February 1, 2007; 92(2): 279 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al.
Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin
Clin. Cancer Res., February 1, 2007; 13(3): 816 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Hillengass, K. Wasser, S. Delorme, F. Kiessling, C. Zechmann, A. Benner, H.-U. Kauczor, A. D. Ho, H. Goldschmidt, and T. M. Moehler
Lumbar Bone Marrow Microcirculation Measurements from Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is a Predictor of Event-Free Survival in Progressive Multiple Myeloma
Clin. Cancer Res., January 15, 2007; 13(2): 475 - 481.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Q. Zhou, L.-Z. Liu, B. Fu, X. Hu, X. Shi, J. Fang, and B.-H. Jiang
Reactive oxygen species regulate insulin-induced VEGF and HIF-1{alpha} expression through the activation of p70S6K1 in human prostate cancer cells
Carcinogenesis, January 1, 2007; 28(1): 28 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Martin, A. L. Dewar, A. N. Farrugia, N. Horvath, S. Gronthos, L. B. To, and A. C.W. Zannettino
Tumor Angiogenesis Is Associated with Plasma Levels of Stromal-Derived Factor-1{alpha} in Patients with Multiple Myeloma
Clin. Cancer Res., December 1, 2006; 12(23): 6973 - 6977.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman
Angiogenesis in Atherogenesis
Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1948 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al.
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
Blood, June 15, 2006; 107(12): 4954 - 4960.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Vincent, D. K. Jin, M. A. Karajannis, K. Shido, A. T. Hooper, W. K. Rashbaum, B. Pytowski, Y. Wu, D. J. Hicklin, Z. Zhu, et al.
Fetal Stromal-Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells
Cancer Res., April 15, 2005; 65(8): 3185 - 3192.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Le Gouill, K. Podar, M. Amiot, T. Hideshima, D. Chauhan, K. Ishitsuka, S. Kumar, N. Raje, P. G. Richardson, J.-L. Harousseau, et al.
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
Blood, November 1, 2004; 104(9): 2886 - 2892.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. P.M. Tjin, P. W.B. Derksen, H. Kataoka, M. Spaargaren, and S. T. Pals
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator
Blood, October 1, 2004; 104(7): 2172 - 2175.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Kumar, T. E. Witzig, M. Timm, J. Haug, L. Wellik, T. K. Kimlinger, P. R. Greipp, and S. V. Rajkumar
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Blood, August 15, 2004; 104(4): 1159 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M G Alexandrakis, F H Passam, C Dambaki, C A Pappa, and E N Stathopoulos
The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma
J. Clin. Pathol., August 1, 2004; 57(8): 856 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
R. A. Kyle, T. M. Therneau, S. V. Rajkumar, D. R. Larson, M. F. Plevak, and L. J. Melton III
Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later
Mayo Clin. Proc., July 1, 2004; 79(7): 859 - 866.
[Abstract] [PDF]

Home page
 BloodHome page
K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
Blood, April 15, 2004; 103(8): 3131 - 3137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Zangari, E. Anaissie, A. Stopeck, A. Morimoto, N. Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, et al.
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
Clin. Cancer Res., January 1, 2004; 10(1): 88 - 95.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Sezer
Exciting times for myeloma research
Blood, November 1, 2003; 102(9): 3081 - 3081.
[Full Text] [PDF]

Home page
 BloodHome page
G. Bisping, R. Leo, D. Wenning, B. Dankbar, T. Padro, M. Kropff, C. Scheffold, M. Kroger, R. M. Mesters, W. E. Berdel, et al.
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
Blood, April 1, 2003; 101(7): 2775 - 2783.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, L. Wellik, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp, et al.
Prognostic value of angiogenesis in solitary bone plasmacytoma
Blood, March 1, 2003; 101(5): 1715 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Kumar, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, S. M. Geyer, N. L. Iturria, R. Fonseca, S. R. Hayman, J. A. Lust, R. A. Kyle, et al.
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
Mayo Clin. Proc., January 1, 2003; 78(1): 34 - 39.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Dingli, M. Timm, S. J. Russell, T. E. Witzig, and S. V. Rajkumar
Promising Preclinical Activity of 2-Methoxyestradiol in Multiple Myeloma
Clin. Cancer Res., December 1, 2002; 8(12): 3948 - 3954.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, S. Hayman, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, P. R. Greipp, S. Geyer, N. Iturria, R. Fonseca, J. A. Lust, et al.
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
J. Clin. Oncol., November 1, 2002; 20(21): 4319 - 4323.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia
Blood, October 16, 2002; 100(9): 3344 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Lin, K. Podar, D. Gupta, Y.-T. Tai, S. Li, E. Weller, T. Hideshima, S. Lentzsch, F. Davies, C. Li, et al.
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment
Cancer Res., September 1, 2002; 62(17): 5019 - 5026.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G
Current Therapy for Multiple Myeloma
Mayo Clin. Proc., August 1, 2002; 77(8): 813 - 822.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
S. V. Rajkumar, R. A. Mesa, R. Fonseca, G. Schroeder, M. F. Plevak, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig, M. A. Gertz, et al.
Bone Marrow Angiogenesis in 400 Patients with Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, and Primary Amyloidosis
Clin. Cancer Res., July 1, 2002; 8(7): 2210 - 2216.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Mesa, C. A. Hanson, C.-Y. Li, S.-Y. Yoon, S. V. Rajkumar, G. Schroeder, and A. Tefferi
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
Blood, May 13, 2002; 99(11): 4131 - 4137.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Lentzsch, M. S. Rogers, R. LeBlanc, A. E. Birsner, J. H. Shah, A. M. Treston, K. C. Anderson, and R. J. D'Amato
S-3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice
Cancer Res., April 1, 2002; 62(8): 2300 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Fonseca, D. Harrington, M. M. Oken, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, E. A. Blood, S. V. Rajkumar, N. E. Kay, et al.
Biological and Prognostic Significance of Interphase Fluorescence in Situ Hybridization Detection of Chromosome 13 Abnormalities ({Delta}13) in Multiple Myeloma: An Eastern Cooperative Oncology Group Study
Cancer Res., February 1, 2002; 62(3): 715 - 720.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist, October 1, 2001; 6(2008): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.